On October 27, 2020 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported it will hold a conference call on November 2, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern (Press release, Anixa Biosciences, OCT 27, 2020, https://ir.anixa.com/news/detail/958/anixa-biosciences-to-host-conference-call-to-provide-update-on-programs [SID1234569135]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Amit Kumar, Anixa’s Chief Executive Officer, will provide an update on the status of the Company’s programs, including the impending filing of an Investigational New Drug (IND) application for its breast cancer vaccine, being developed with the Cleveland Clinic, the progress with its CAR-T treatment for ovarian cancer, being developed with the Moffitt Cancer Center, and the latest discoveries with its Covid-19 therapy.

Conference Call Information:
Interested participants and investors may access the conference call by dialing:

(877) 876-9174
Conference ID: Anixa
An audio webcast will be accessible via the Investors section of the Anixa website at View Source An archive of the webcast will remain available for 30 days after the call.